The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
18 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $51,183,322 in first-year total cost, median $2,436,994.
Most frequent study sections
- Medication Development Research Study Section[NIDA-L]15
- Special Emphasis Panel[ZDA1 IXN-O (04)]3
Most frequent institutions
- INTERVEXION THERAPEUTICS, LLC3
- CLEAR SCIENTIFIC, LLC2
- ANTIDOTE THERAPEUTICS, INC.1
- ASTRAEA THERAPEUTICS, LLC1
- CESSATION THERAPEUTICS, LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Clinical Development of a Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication1U01DA058548-01 | LI, XINHUA | CLEAR SCIENTIFIC, LLC, MA | $4,069,920 | NIDA |
| 2023 | IND-enabling Studies in Support of First in Human Safety Studies of a Novel Anti-Nicotine Human Monoclonal Antibody1U01DA058547-01 | KALNIK, MATTHEW W | ANTIDOTE THERAPEUTICS, INC., MD | $4,026,705 | NIDA |
| 2023 | PDE7 Inhibitor for the Treatment of Cocaine Use Disorder1U01DA058541-01 | GAITANARIS, GEORGE | OMEROS CORPORATION, WA | $1,382,131 | NIDA |
| 2022 | Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder1U01DA057862-01 | LEVIN, FRANCES RUDNICKLEVY, DANIELTOLL, LAWRENCE R | PHOENIX PHARMALABS, INC., UT | $2,680,161 | NIDA |
| 2022 | Development of TNX-1300 (Double Mutant Cocaine Esterase) for the Treatment of Life-Threatening Cocaine Intoxication1U01DA056245-01 | SULLIVAN, GREGORY M | TONIX PHARMACEUTICALS, INC., NJ | $2,556,716 | NIDA |
| 2022 | TMP-301, A Negative Allosteric Modulator of type 5 metabotropic glutamate receptors (mGluR5), for Treatment of Cocaine Use Disorder1U01DA057118-01 | MEYERS, CHARLES DANIEL | TEMPERO BIO, INC., CA | $2,060,520 | NIDA |
| 2022 | Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder1U01DA057846-01 | ARIAS, ALBERT JOSEPHBJORK, JAMES M | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $1,597,923 | NIDA |
| 2022 | An automated portable system for detecting and treating opioid induced respiratory depression1U01DA056242-01 | GUO, FENGMACKIE, KENNETH | TRUSTEES OF INDIANA UNIVERSITY, IN | $1,349,487 | NIDA |
| 2022 | IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder1U01DA056240-01 | STEVENS, MISTY WARD | INTERVEXION THERAPEUTICS, LLC, AR | $1,248,915 | NIDA |
| 2021 | Preclinical Development of Novel Dual OXR/KOR Antagonists for Treatment of Substance Use Disorder1UF1DA054817-01A1 | BUTERA, JOHN A | HAGER BIOSCIENCES, LLC, PA | $5,598,515 | NIDA |
| 2021 | OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder1U01DA055481-01 | GENTRY, W BROOKSSTEVENS, MISTY WARD | INTERVEXION THERAPEUTICS, LLC, AR | $4,597,509 | NIDA |
| 2021 | Development of a novel OTC naloxone product to be affordably priced and widely accessible1UF1DA053806-01A1 | MATHAI, ASHANTHI | POCKET NALOXONE CORP., MD | $2,381,970 | NIDA |
| 2021 | First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence1U01DA054882-01 | PERKINS, KENNETH ALANZAVERI, NURULAIN T | ASTRAEA THERAPEUTICS, LLC, CA | $2,007,282 | NIDA |
| 2021 | The CB1 Signaling-Specific Inhibitor, AEF0117, for Cannabis Use Disorder: A Multi-Site Treatment Trial1U01DA053832-01 | LEVIN, FRANCES RUDNICK | NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC, NY | $1,594,372 | NIDA |
| 2021 | 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder1U01DA052174-01A1 | JOHNSON, MATTHEW WAYNE | JOHNS HOPKINS UNIVERSITY, MD | $1,499,440 | NIDA |
| 2020 | Process Development, Manufacturing, and Preclinical Evaluation of a Monoclonal Antibody for Fentanyl Overdose1U01DA051071-01A1 | BREMER, PAUL T | CESSATION THERAPEUTICS, LLC, CA | $6,107,502 | ZDA1 |
| 2020 | Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication1U01DA053054-01 | LI, XINHUA | CLEAR SCIENTIFIC, LLC, MA | $3,932,236 | ZDA1 |
| 2020 | Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS1U01DA053043-01 | GENTRY, W BROOKSSTEVENS, MISTY WARD | INTERVEXION THERAPEUTICS, LLC, AR | $2,492,018 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.